Drug Trial Radar · NCT06024239
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Aug 31, 2023
Primary completion
Mar 4, 2025
Study completion Mar 4, 2025
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD).
Conditions
- Healthy Volunteers
- Generalized Anxiety Disorder (GAD)
- Bipolar Disorder (BPD)
Interventions
ABBV-932Drug
Capsule; oral
Placebo for ABBV-932Drug
Capsule; oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax)Time frame: Up to Day 28
- Time to Cmax (Tmax)Time frame: Up to Day 28
- Plasma Concentrations at Pre-dose or at the End of a Dosing Interval (Ctrough)Time frame: Up to Day 28
- Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau)Time frame: Up to Day 28
- Number of Participants with Adverse Events (AEs)Time frame: Baseline to Day 129
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Collaborative Neuroscience Research CNS /ID# 260270
Los Alamitos, California
Acpru /Id# 255945
Grayslake, Illinois
Hassman Research Institute Marlton Site /ID# 260271
Marlton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.